Internet Archive Scholar

Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, María Pérez Abánades, Silvia Ruíz-García, Ana Beatriz Fernández Román, Javier Letellez Fernández, Beatriz Candel García, Carlos Hernández Terciado, Raquel De Santiago Álvarez, Rebeca Mondéjar Solis, Berta Hernández Marin, Patricia Toquero Diez, Alberto Morell Baladrón (+1 others)
2022

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (39.3 MB)
https://web.archive.org/web/20221223150804/https://cdn.sanity.io/files/0vv8moc6/cancernetwork/cf984826270c5356acc3619859280fa4338594c7.pdf/ONC1222_Ezine_v2.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

To assess the effectiveness and toxicity of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice, as well as predictive factors of effectiveness. This was a retrospective multicenter study in patients with mCRC who received regorafenib from November 2013 to May 2020. Effectiveness was evaluated by overall survival (OS) and progression-free survival (PFS) using the Kaplan-Meier method. Cox regression was performed to determine survival predictors. Ninety
more » ... atients were enrolled (median age, 64.3 years). Fifty-two patients (57.8%) were male, and 57 (63.3%) had an ECOG performance status (PS) of 0 to 1. Median follow-up was 2.80 months. Median OS was 8.03 months (95% CI, 5.90-10.17), and median PFS was 2.90 months (95% CI, 2.59-3.21). Eighty-eight patients (97.8%) experienced drug-related adverse events. The most frequent were fatigue in 66 patients (73.3%), followed by palmar-plantar erythrodysesthesia in 40 (44.4%). Low liver tumor burden score (LTBS) and good ECOG PS were independent OS predictive factors. Patients taking regorafenib had OS and PFS rates similar to those reported in previous randomized trials; the agent had a poor toxicity profile. We identified low LTBS and good ECOG PS as possible predictive factors of better OS, useful in selecting patients with mCRC who might benefit from regorafenib.
doi:10.46883/2022.25920981 pmid:36548097 fatcat:ewf7nqkm4zfptifpp2g4c4ucp4
Citation

Alberto Calvo-García, María Pérez Abánades, Silvia Ruíz-García, Ana Beatriz Fernández Román, Javier Letellez Fernández, Beatriz Candel García, Carlos Hernández Terciado, Raquel De Santiago Álvarez, Rebeca Mondéjar Solis, Berta Hernández Marin, Patricia Toquero Diez, Alberto Morell Baladrón, Ramón Colomer Bosch. "Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data." (2022) 732-738